An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * CABOMETYX® Receives FDA Approval to Treat Neuroendocrine Tumors On March 26, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with […]
Pharma Fridays – March 28, 2025
Join the Global Movement Advancing Endocrine Science and Medicine
Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.